Telehealth company
SkinnyRx
Client-rendered React app; verified via published application bundle and structured data
Telehealth service profile
- Care model
- Online GLP-1 weight-loss clinic offering compounded semaglutide and tirzepatide in injectable, tablet, and sublingual forms
- Medication access
- Compounded semaglutide and tirzepatide prescribed after a pre-qualification medical intake; payment processed only after intake, with a full refund if the provider declines.
- Provider model
- US-based licensed, board-certified providers; refill check-ins handled by email and the patient portal.
- Pharmacy pathway
- 503A compounding pharmacies licensed by state boards of pharmacy; free overnight delivery advertised.
- Insurance support
- No insurance required; all major credit cards accepted, HSA/FSA eligible.
- Availability
- Eligibility determined by provider review of the medical intake; not charged if not eligible.
Editorial record
SkinnyRx is a single-focus GLP-1 provider whose embedded product data lists compounded oral semaglutide at $199, injectable semaglutide at $199, semaglutide tablets at $249, and injectable or tablet tirzepatide at $299. FAQ copy states prescriptions are dispensed by 503A pharmacies licensed by state boards, no insurance is required, and patients deemed ineligible receive a full refund within 24-48 hours. The site is a client-rendered React app, so details were verified from its published application bundle.
Profile ownership: unclaimed. Company representatives will be able to propose identity and catalog updates without changing editorial or regulatory records.